MedTrace Logo

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

NCT00826527 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2009-01-22

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that solifenacin post-operatively improves irritative symptoms in men whose obstructive symptoms have been relieved with the GreenLight laser outpatient procedure.

Conditions

  • Urinary Frequency
  • Urinary Urgency
  • Nocturia

Interventions

DRUG

Solifenacin PO

Tab 5 mg Daily for 12 Weeks

Sponsors & Collaborators

  • Seattle Urology Research Center

    lead OTHER

Principal Investigators

  • Jeffrey M Frankel, MD · Seattle Urology Research Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00826527 on ClinicalTrials.gov